Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or…

Posted: December 26, 2022 at 12:12 am

- FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA -

Link:
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or...

Related Posts